Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RedPath Integrated Pathology, a molecular diagnostics company, has appointed Mark Myslinski as its new president and CEO. Mr Myslinski replaces founding CEO, Mary Brady, who remains an active investor in the company.
Subscribe to our email newsletter
Mr Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide evidence based medicine function for the ortho-clinical diagnostics unit.
Mr Myslinski was also general manager of Johnson & Johnson’s Veridex, a division focused on molecular diagnostics. Previously, Mr Myslinski held executive roles in venture-backed start-ups, Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer.
Brian Murphy, non-executive chairman of RedPath, said: “Mark is a seasoned executive with considerable experience in developing novel diagnostics for broad market adoption. As we prepare to further penetrate the market for RedPath’s PathFinderTG, a diagnostic platform that resolves diagnostic dilemmas, to a broader audience of clinicians, pathologists, patients and payor organizations, Mark’s track record in these areas clearly made him our top choice.”